Nasopharyngeal Carcinoma (NPC)
Conditions
Brief summary
To analyze the spatiotemporal dynamic evolution of nasopharyngeal carcinoma before and after immunotherapy and during tumor progression, 2\ 3 key cell subsets or node molecules were screened to predict the curative effect. Spatial metabolome and organoids were used to elucidate the mechanism of key factors leading to immunotherapy tolerance in NPC and identify new targets for intervention.
Interventions
OTHERNo Intervention
This project involves no therapeutic intervention for the subjects.
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
15 Years to 75 Years
Inclusion criteria
Before the trial, the participants must meet all of the following requirements to be eligible for inclusion. 1. Clearly diagnosed with nasopharyngeal carcinoma by pathology; 2. Patients who have received combined radiotherapy, chemotherapy and immunotherapy in our hospital; 3. Patients diagnosed in our hospital from January 2025 to December 2028; 4. Have relatively complete clinical data; 5. Age between 15 and 75 years old;
Exclusion criteria
Before the trial, the participants who meet any of the following requirements cannot be included. 1. The final diagnosis of the participants is other diseases, including lymphoma, or oropharyngeal cancer, etc.; 2. The participants failed to obtain pathological and imaging data for various reasons; 3. Due to physical conditions, they did not undergo relevant examinations, refused to accept examinations, or interrupted treatment for other reasons, and were unable to complete clinical assessment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Failure-free survival (FFS) | 3-year | Failure-free survival is measured from day of diagnosis until treatment failure, death from any cause, or last follow-up visit, whichever occurred first |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | 5-year | Overall survival is measured from day of diagnosis until death due to any cause or the latest known date alive |
Outcome results
None listed